Functional assessment of HDL: Moving beyond static measures for risk assessment

Cardiovasc Drugs Ther. 2010 Feb;24(1):71-5. doi: 10.1007/s10557-009-6214-3.
No abstract available

Publication types

  • Congress

MeSH terms

  • Amides
  • Animals
  • Anticholesteremic Agents / therapeutic use
  • Azetidines / adverse effects
  • Azetidines / pharmacology
  • Azetidines / therapeutic use
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / prevention & control
  • Cholesterol / metabolism
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors
  • Cholesterol Ester Transfer Proteins / genetics
  • Cholesterol, HDL / blood
  • Cholesterol, HDL / drug effects
  • Cholesterol, HDL / genetics
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects
  • Clinical Trials as Topic
  • Esters
  • Ezetimibe
  • Glucose / metabolism
  • Humans
  • Insulin / metabolism
  • Lipase / physiology
  • Lipoproteins, HDL / physiology*
  • Niacin / adverse effects
  • Niacin / pharmacology
  • Niacin / therapeutic use
  • Quinolines / adverse effects
  • Quinolines / pharmacology
  • Quinolines / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Sulfhydryl Compounds / pharmacology
  • Sulfhydryl Compounds / therapeutic use

Substances

  • Amides
  • Anticholesteremic Agents
  • Azetidines
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Esters
  • Insulin
  • Lipoproteins, HDL
  • Quinolines
  • Sulfhydryl Compounds
  • Niacin
  • dalcetrapib
  • torcetrapib
  • Cholesterol
  • LIPG protein, human
  • Lipase
  • Ezetimibe
  • Glucose